Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  CNS Drugs

• Publication date

  2026-03-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40263-026-01281-0PMID 41774409
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Intranasal Seletracetam in a Patient with Reading Epilepsy: First‐in‐Human Use to Prevent Reflex Seizures

  2025cited by this paper
• Exploring proposed recommendations for immediate‐use seizure medication: Treating both cluster and prolonged seizures with diazepam nasal spray

  2025cited by this paper
• The human photosensitive epilepsy model for clinical proof‐of‐principle trials of novel antiseizure medications: 2. Analysis of drug trials and predictive value of the model

  2025cited by this paper
• Excitatory Amino Acid Transporters as Therapeutic Targets in the Treatment of Neurological Disorders: Their Roles and Therapeutic Prospects

  2025cited by this paper
• Milestone Review: Unlocking the Proteomics of Glycine Receptor Complexes

  2025cited by this paper
• Pharmacodynamic interactions between seletracetam and antiseizure comedications in the human photosensitivity model

  2025cited by this paper
• Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy

  2025cited by this paper
• Glycine receptors: Structure, function, and therapeutic implications.

  2025cited by this paper
• From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications.

  2025cited by this paper
• Control of Synaptotagmin‐1 Trafficking by SV2A—Mechanism and Consequences for Presynaptic Function and Dysfunction

  2025cited by this paper
• A multicenter Phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients.

  2025cited by this paper
• Structural insights into SV2A and the mechanism of racetam anticonvulsants

  2024cited by this paper
• Intranasal Versus Buccal Versus Intramuscular Midazolam for the Home and Emergency Treatment of Acute Seizures in Pediatric Patients: A Randomized Controlled Trial.

  2024cited by this paper
• Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: Consensus recommendations of an expert working group.

  2024cited by this paper
• Animal Models of Drug-Resistant Epilepsy as Tools for Deciphering the Cellular and Molecular Mechanisms of Pharmacoresistance and Discovering More Effective Treatments

  2023cited by this paper
• Synaptic Vesicle Glycoprotein 2A: Features and Functions

  2022cited by this paper
• Seizure clusters

  2021cited by this paper
• The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond

  2021cited by this paper
• Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: opportunities for novel therapeutics development.

  2021cited by this paper
• A systematic review of seizure clusters: Prevalence, risk factors, burden of disease and treatment patterns.

  2021cited by this paper
• Intranasal Allopregnanolone Confers Rapid Seizure Protection: Evidence for Direct Nose-to-Brain Delivery

  2021cited by this paper
• Seizure clusters, rescue treatments, seizure action plans: Unmet needs and emerging formulations.

  2020cited by this paper
• Review on Buccal Drug Delivery System

  2020cited by this paper
• Mechanisms of action of currently used antiseizure drugs.

  2020cited by this paper
• The synaptic vesicle glycoprotein 2: structure, function, and disease relevance.

  2019cited by this paper
• The Current Approach of the Epilepsy Therapy Screening Program Contract Site for Identifying Improved Therapies for the Treatment of Pharmacoresistant Seizures in Epilepsy.

  2019cited by this paper
• Endothelial Cdk5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis

  2019cited by this paper
• Zinc signaling and epilepsy

  2019cited by this paper
• Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

  2018cited by this paper
• Prevalence and predictors of seizure clusters: A prospective observational study of adult patients with epilepsy.

  2018cited by this paper
• Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

  2017cited by this paper
• Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies.

  2016cited by this paper
• Benzodiazepine use in seizure emergencies: A systematic review.

  2016cited by this paper
• [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.

  2016cited by this paper
• Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

  2016cited by this paper
• A review of intranasal formulations for the treatment of seizure emergencies.

  2016cited by this paper
• Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond

  2016cited by this paper
• Benzodiazepine use, misuse, and abuse: A review

  2016cited by this paper
• Pharmacotherapy for Status Epilepticus

  2015cited by this paper
• Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations

  2015cited by this paper
• Intranasal therapies for acute seizures.

  2015cited by this paper
• Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: A systematic review with meta-analysis.

  2015cited by this paper
• A Common Reference-Based Indirect Comparison Meta-Analysis of Buccal versus Intranasal Midazolam for Early Status Epilepticus

  2015cited by this paper
• Ceftriaxone Treatment after Traumatic Brain Injury Restores Expression of the Glutamate Transporter, GLT-1, Reduces Regional Gliosis, and Reduces Post-Traumatic Seizures in the Rat

  2013cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Seletracetam (UCB 44212)

  2011cited by this paper
• Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

  2011cited by this paper
• Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.

  2010cited by this paper
• Intranasal delivery of antiepileptic medications for treatment of seizures

  2009cited by this paper
• Seletracetam (ucb 44212) inhibits high‐voltage–activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro

  2009cited by this paper
• Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.

  2009cited by this paper
• Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).

  2007cited by this paper
• Levetiracetam: the first SV2A ligand for the treatment of epilepsy

  2007cited by this paper
• Nasal drug administration: potential for targeted central nervous system delivery.

  2005cited by this paper
• β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

  2005cited by this paper
• Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.

  2004cited by this paper
• The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

  2004cited by this paper
• The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents

  2002cited by this paper
• Zinc-Induced Collapse of Augmented Inhibition by GABA in a Temporal Lobe Epilepsy Model

  1996cited by this paper
• A note on a simple apparatus for detecting neurological deficit in rats and mice.

  1957cited by this paper
• Send Orders of Reprints at Reprints@benthamscience.org Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine Delivery

  year unknowncited by this paper

• No citing papers are available for this paper.